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Abstract: Fenofibrate-loaded electrospun microfibrous sheets were prepared in an attempt to enhance
the dissolution of the poorly soluble antihyperlipidemic agent and to improve its bioavailability.
Physicochemical changes that appeared during the electrospinning process were monitored using
a wide array of solid-state characterization techniques, including attenuated total reflectance
Fourier-transformed infrared spectroscopy and positron annihilation lifetime spectroscopy, while fiber
morphology was monitored via scanning electron microscopy. Dissolution studies carried out both
in 0.025 M sodium dodecyl sulfate and in water revealed an immediate release of the active agent,
with an approximately 40-fold release rate enhancement in water when compared to the micronized
active agent. The dramatic increase in dissolution was attributed partially to the amorphous form of
the originally crystalline active agent and the rapid disintegration of the electrospun microfibrous
sheet due to its high surface area and porosity. The obtained results could pave the way for a
formulation of the frequently used antihyperlipidemic agent with increased bioavailability.
Keywords: electrospinning; microfibers; Positron Annihilation Lifetime Spectroscopy (PALS);
dissolution enhancement; amorphization
1. Introduction
As high-throughput methods emerge in the process of drug discovery, numerous promising
candidates are appearing that present high affinity for the identified molecular targets. However,
the chase for highly potent drugs often comes at the cost of undesirable physical properties,
such as high lipophilicity, high molecular weight, and low solubility [1,2]. Drugs of low solubility
account for almost 75% of all drug candidates, further increasing the burden on pharmaceutical
technologists trying to deliver adequate enabling formulations for these compounds [3,4]. Over the
years, various formulation strategies have been successfully applied for low-solubility drugs,
such as particle-size reduction, lipid-based vehicles, preparation of solid dispersions, salt formation,
amorphization, co-crystal formation, and cyclodextrin complexation [5–7].
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Fenofibrate (FEN, Figure 1a) as a model drug of extremely low solubility, is an ester derivative
of the pharmacologically active fibric acid, which acts as a peroxisome proliferator-activated
receptor-α (PPARα) agonist, reducing concentrations of plasma triglycerides and improving the
ratio of high-density lipoprotein/low-density lipoprotein choresterol [8]. Unfortunately, among the
numerous fibric acid derivatives available worldwide, FEN exhibits the lowest and most variable
bioavailability. The molecule is neutral, highly lipophilic (logP = 5.4), and virtually insoluble in
water [8], belonging to Biopharmaceutical Classification System (BCS) Class II. For BCS Class II drugs,
solubility is the rate-limiting step in absorption. In order to overcome this problem, numerous fenofibrate
formulations have been developed, and an excellent review [9] was also published about the available
fenofibrate and fenofibric acid formulations Versatile types of formulations, e.g., micronized [10,11],
microcoated [12,13], insoluble drug delivery microparticulate formulations [14], self-emulsifying drug
delivery systems [15–17], nanoparticulate formulations [18–21], thin film freezing [22], incorporation
in mesoporous silica [23–28], or carbon [29] have appeared in the last decade.
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Figure 1. Chemical structures of (a) FEN and (b) PVP. 
In recent years, electrostatic spinning (electrospinning) has emerged as the most dynamically 
growing technique for the generation of artificial fibrous architectures [30,31]. For drug delivery 
applications, fibers are produced usually from drug-loaded, viscous polymeric solution by applying 
high voltage, during which liquid droplets are electrified for the generation of initial jets, followed 
by stretching and elongation to produce fibers [30,32]. The obtained non-woven fibrous mats are 
characterized by large surface areas, porous structure, and the possibility of controlling the 
crystalline–amorphous transition of the active ingredient [32,33]. Owing to these advantages, 
nanofiber-based drug delivery systems are also under intensive study as a promising way to develop 
oral, fast-dissolving pharmaceutical dosage forms [32,34–37]. Besides the pharmaceutical and tissue 
engineering applications of nanofibrous systems, they are frequently applied for a wide variety of 
other purposes as well, e.g., filtration, affinity membranes and recovery of metal ions, catalyst and 
enzyme carriers, and energy storage [38,39]. 
The aim of this study was to prepare a fenofibrate-loaded drug delivery system based on 
polyvinylpyrrolidone (PVP, Figure 1b) fibers with the aid of electrospinning, intended for fast drug 
release in the buccal cavity. The microstructural characterization of prepared fibrous meshes, 
including the tracking of the physicochemical changes of electrospun fibers, was also in the focus of 
the present work. 
2. Materials and Methods 
2.1. Materials 
The micronized FEN was a kind gift from a local pharmaceutical company in Tirgu Mures, 
Romania. PVP (Plasdone K-29/32) was obtained from ISP Technologies/Ashland, (Wayne, NJ, USA). 
Kolliphor RH 40, Kollisolv P124, Kolliphor EL were obtained from BASF (Limburgerhof, Germany); 
polysorbate 80 (Tween 80) was from Sigma-Aldrich (St. Louis, MO, USA); methanol, acetonitrile 
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In recent years, electrostatic spinning (electrospinning) has emerged as the most dynamically
growing technique for the generation of artificial fibro s architectures [30,31]. For drug delivery
applications, fibers are produced usually fro l aded, viscous polymeric solution by applying
high voltage, during whic liquid droplets are l ctrified for the g i of initial jets, followed by
stretching and elongation to produce fibers [30,32]. The obtained non-woven fibrous mats are
characterized by large surface areas, porous structure, and the possibility of controlling the
crystalline–amorphous transition of the active ingredient [32,33]. Owing to these advantages,
nanofiber-based drug delivery systems are also under intensive study as a promising way to develop
oral, fast-dissolving pharmaceutical dosage forms [32,34–37]. Besides the pharmaceutical and tissue
engineering applications of nanofibrous systems, they are frequently applied for a wide variety of
other purposes as well, e.g., filtration, affinity membranes and recovery of metal ions, catalyst and
enzyme carriers, and energy stor ge [38,39].
The aim of th s study was to prepare a fenofibrate-loaded drug delivery system based on
polyvinylpyrrolidone (PVP, Figure 1b) fibers with the aid of electrospinning, intended for fast
drug release in the buccal cavity. The microstructural characterization of prepared fibrous meshes,
including the tracking of the physicochemical changes of electrospun fibers, was also in the focus of
the present work.
2. Materials and Methods
2.1. Materials
The micronized FEN was a kind gift from a local pharmaceutical company in Tirgu Mures,
Romania. PVP (Plasdone K-29/32) was obtained from ISP Technologies/ shland, (Wayne, NJ, USA).
Kolliphor RH 40, Kollisolv P124, Kolliphor EL were obtained from BASF (Limburgerhof,
Germany); polysorbate 80 (Tween 80) was from Sigma-Aldrich (St. Louis, MO, USA); methanol,
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acetonitrile (gradient grade, Merck, Darmstadt, Germany), and sodium dodecyl sulfate (SDS, Merck,
Darmstadt, Germany) were obtained through local vendors.
2.2. Preparation of Microfibrous Sheets by Electrospinning
First, 0.2 g FEN, 0.5 g polysorbate 80, and 2.4 g PVP were dissolved in 5 mL ethanol by magnetic
stirring at 500 rpm using a JK SMS HS magnetic stirrer (JKI, Shanghai, China), until a clear viscous
solution was obtained, which was transferred into a 20 mL plastic syringe. Drug-loaded microfibrous
sheets were prepared by electrospinning using an in-house-assembled apparatus, employing the
following parameters: 0.7 mL/h flow rate, provided by an Ascor AP 12 syringe pump (Ascor Med,
Warsaw, Poland), the spinneret had a 1.5 mm internal diameter, a blunt metal needle that was connected
to the 5 mL syringe with silicone tubing; the spinneret-to-collector distance was set to 7.5 cm and
15 kV voltage was applied. A 10–20 min continuous operation resulted in sheets of uniform diameter
and thickness.
2.3. Morphology Investigation by Scanning Electron Microscopy (SEM)
The fiber mat morphology and the fiber diameter were investigated by SEM imaging, with the
use of a JEOL JSM-5200 scanning electron microscope (JEOL, Tokyo, Japan) at 15 kV potential.
The samples were used as is (without sputter coating) and were fixed by conductive carbon adhesive
tape. SEM images were taken at different parts of the sample in order to determine the average fiber
diameter. Diameters of 130 randomly selected individual fibers were measured using ImageJ software
version 1.53C (US National Institutes of Health, Bethesda, MD, USA).
2.4. ATR-FTIR Spectroscopic Examinations
ATR-FTIR spectra were collected on Jasco FT/IR-4200 spectrophotometer (Jasco Inc.,
Easton, MD, USA) between 4000 and 400 cm−1 with an ATRPRO470-H single reflection accessory
(Jasco) equipped with flat pressure tip. The spectral measurements were performed in absorbance
mode. The 100 scans at a resolution of 4 cm−1 were co-added by the FTIR software (Spectra Manager-II,
Jasco). FEN, PVP K-29/32 and polysorbate 80 were measured as single compounds and as physical
mixtures; afterwards, spectra of the drug-loaded microfibers were also recorded.
2.5. Determination of Drug Content of FEN-Loaded Microfibers
Drug content of the microfibrous mats was determined using a Shimadzu UV-1601PC UV-VIS
spectrophotometer (Shimadzu, Tokyo, Japan). Approximately 10 mg microfiber was accurately
weighted in a 50 mL volumetric flask, dissolved in 25 mM sodium dodecyl sulfate solution, and
completed to sign. Absorbances of the prepared solutions (n = 4) were measured at 289 nm in a 10 mm
quartz cuvette (Merck, Germany), and concentrations were calculated on the basis of a calibration curve.
2.6. Dissolution Studies
Dissolution tests were carried out in an Erweka DT-80 dissolution apparatus (Erweka GmbH,
Heusenstam, Germany) equipped with rotating baskets (Apparatus 1). The temperature of the
dissolution medium was maintained at 37.0 ± 0.5 ◦C, and rotation speed was set at 100 rpm.
Dissolution studies were performed in two separate dissolution media, both at a volume of 500 mL:
water and 0.025 M sodium dodecyl sulfate. Sampling was performed manually at 1, 3, 5, 10, 20,
and 30 min, by withdrawing 3 mL of samples with a syringe. The aliquots were filtered and the
dissolved FEN content was determined spectrophotometrically, using a Shimadzu UV-1601PC UV-VIS
spectrophotometer at 289 nm, in a 10 mm quartz cuvette.
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2.7. Positron Lifetime Measurements
Supramolecular characterization of samples was carried out using positron annihilation lifetime
spectroscopy (PALS). For ortho-positronium (o-Ps) lifetime determination, carrier-free 22NaCl positron
source of activity of 105–106 Bq, sealed between two thin Kapton® foils, was used with a fast–fast
coincidence system based on BaF2 /XP2020Q detectors and Ortec® electronics. The fibrous samples or
the physical mixtures were placed at either side of the source (forming a sandwich structure), and were
finally wrapped in aluminum foil. Three parallel spectra were measured at each composition to increase
reliability. After summarizing the parallels, spectra were evaluated using the RESOLUTION computer
code [40]; the indicated errors are the deviations of the lifetime parameters obtained. Two lifetime
components were found in each sample, and the longest component was identified as the o-Ps lifetime,
which is related to the annihilation of the o-Ps atoms.
3. Results and Discussion
Numerous preformulation experiments were performed in order to obtain a homogenous solution
with adequate drug loading which would be suitable for electrospinning. PVP K-29/32 was selected as
the fiber-forming polymer, which could be easily electrospun into microfibrous meshes when used
in a concentration of 40% w/v in ethanol or methanol. However, FEN alone could not be dissolved
in satisfactory concentration in the alcoholic PVP solutions; thus, several solubilizers (Kolliphor RH
40, Kollisolv P124, Kolliphor EL, and polysorbate 80) were tested in order to overcome this issue.
Satisfactory results were obtained when FEN was dispersed in polysorbate 80 and dissolved afterwards
in a 40% w/v PVP K-29/32 ethanolic viscous solution. The obtained solution was electrospun into a
beadless, well-defined, randomly aligned fibrous structure, as observed in Figure 2. The obtained
microfibers presented uniform structures with smooth surfaces. Mean fiber diameter as determined by
SEM imaging was 1.10 ± 0.23 µm.
Pharmaceutics 2020, 12, 612 4 of 10 
 
2.7. Positron Lifetime Measurements 
Supramolecular characterization of samples was carried out using positron annihilation lifetime 
spectroscopy (PALS). For ortho-positronium (o-Ps) lifetime determination, carrier-free 22NaCl 
positron source of activity of 105–106 Bq, sealed between two thin Kapton® foils, was used with a fast–
fast coincidence system based on BaF2 /XP2020Q detectors and Ortec® electronics. The fibrous 
samples or the physical mixtures were placed at either side of the source (for ing a sandwich 
structure), and were finally wrapped in aluminum foil. Three parallel spectra were measured at each 
composition to increase r liability. Aft r summarizing t  parallels, spectra were evaluated using the 
RESOLUTION computer code [40]; the indica ed errors are the deviation  of the lifetime parameters 
obtained. Two life ime components wer  found in each sample, and the longest component was 
identified as the o-Ps lifetime, which is related to the annihilation of the o-Ps atoms. 
3. Results and Discussion 
Numerous pref rmulation experiments were performed in order to obtain a homog nous 
solution with adequate drug loading which would be suitable for electrospinning. PVP K-29/32 was 
selected as the fiber-forming polymer, which could be easily electrospun into microfibrous meshes 
when used in a concentration of 40% w/v in ethanol or methanol. However, FEN alone could not be 
dissolved in satisfactory concentration in the alcoholic PVP solutions; thus, several solubilizers 
(Kolliphor RH 40, Kollisolv P124, Kolliphor EL, and polysorbate 80) were tested in order to overcome 
this issue. Satisfactory results were obtained when FEN was dispersed in polysorbate 80 and 
dissolved afterwards in a 40% w/v PVP K-29/32 ethanolic viscous solution. The obtained solution was 
electrospun into a beadless, well-defined, randomly aligned fibrous structure, as observed in Figure 
2. The obtained microfibers presented uniform structures with smooth surfaces. Mean fiber diameter 





Figure 2. SEM images of the obtained electrospun microfibers at (a) 500× and (b) 2000× magnification 
and their diameter distributions (b). 
FEN content of the electrospun PVP-based microfibers was determined to be 6.65 ± 0.09% w/w, 
indicating homogenous FEN dispersion and repeatability among the different microfibrous mesh 
batches obtained through 10–20 min continuous electrospinning. 
Sequential photographs taken at an interval of 1 s depicting the immersion of an electrospun 
microfibrous mesh are shown in Figure 3. Due to its high surface area-to-volume ratio and high 
porosity, the fibrous material showed immediate disintegration when it came into contact with water. 
After disintegration, a clear solution was obtained, without the precipitation of FEN. 
Figure 2. SEM images of the obtained electrospun microfibers at (a) 500× and (b) 2000×magnification
and their diameter distributions (b).
FEN content of the electrospun PVP-based microfibers was determined to be 6.65 ± 0.09% w/w,
indicating ho ogenous FEN dispersion and repeatability among the different microfibrous mesh
batches obtained through 10–20 in continuous electrospinning.
Seque ti l t raphs taken at an interval of 1 s depicting the i mersi n of an electrospun
microfibro in Figure 3. Due to its high surface area t -volume ratio and high
porosity, the fibr l sho ed immediate d sintegration when it came into contact with water.
After disintegr ti l tion was obtained, without the prec pitation of FEN.
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0.025 M sodium dodecyl sulfate was selected as an alternative dissolution medium, as this is also the 
one suggested by the FDA dissolution database for micronized FEN-containing capsules. As shown 
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higher than 80% at the first sampling point for the microfibrous formulation, regardless of the 
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only approximately 2%, when using water as the dissolution medium. In comparison, dissolution 
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micronized API. 
Figure 3. Sequential photographs of the disintegration process of the obtained microfibrous mesh.
Dissolution behavior of the prepared microfibers (test formulation) was compared directly to
the micronized active ingredient (control) in two separate dissolution media. Since the model drug
was neutral, water was selected as the first, more discriminative dissolution medium. Additionally,
0.025 M sodium dodecyl sulfate was selected as an alternative dissolution medium, as this is also the
one suggested by the FDA dissolution database for micronized FEN-containing capsules. As shown in
Figure 4, the microfibrous formulation outperformed the API in both cases: drug release was higher than
80% at the first sampling point for the microfibrous formulation, regardless of the dissolution medium
employed. In the case of the micronized API, dissolution was extremely low, only approximately
2%, when using water as the dissolution medium. In comparison, dissolution from the microfibers
remained at around 80% throughout the study, which translates to a very high, approximately 40-fold
increase in dissolution rate of FEN when the active agent was incorporated into the microfibers.
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Figure 3. Sequential photographs of the disintegration process of the obtained microfibrous mesh.
Dissolution behavior of the prepared microfibers (test formulation) was compared directly to
the micronized active ingredient (control) in two separate dissolution media. Since the model drug
was neutral, water was selected as the first, more discriminative dissolution medium. Additionally,
0.025 M sodium dodecyl sulfate was selected as an alternative dissolution medium, as this is also the
one suggested by the FDA dissolution database for micronized FEN-containing capsules. As shown in
Figure 4, the microfibrous formulation outperformed the API in both cases: drug release was higher than
80% at the first sampling point for the microfibrous formulation, reg rdless of th di solution medium
employed. In the case f the micron zed API, dissolution was ext emely low, only approximately
2%, when using water as the dissolution medium. In c mparison, dissolution from the microfibers
remained at around 80% throughout the stu y, which transl te to a very high, approx mately 40-fold
increase in dissolution rate of FEN when the active age t was incorporated into the microfibers.
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Using the FDA-recommended 0.025 M SDS medium, dissolution of the micronized API was
higher; however, the dissolution rate was slow: 14.53% at 1 min, which increased slowly to 55.54% at
the end of the dissolution test, at 30 min. In comparison, FEN dissolution was immediate from the
Pharmaceutics 2020, 12, 612 6 of 10
microfibrous sheets (91.39% at 1 min and 91.98% at 30 min). No precipitation of the active agent was
observed after 30 min.
The obtained ATR-FTIR spectra are shown in Figure 5. The spectrum of FEN (Figure 5a) showed
peaks resulting from the CH of the aromatic rings at approximately 3050 cm−1, whereas the CH3 peaks
presented at lower values of approximately 2950 cm−1. The characteristic peaks at 1730–1550 cm−1
corresponded to the carbonyl of the ketone and ester group, as shown in the chemical structure of the
drug (Figure 1a).
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The physical mixtures with and without polysorbate 80 (Figure 5d,e) presented all the characteristic
peaks of the individual components.
Comparing the spectrum of the drug-loaded microfibers (Figure 5f) to that of the physical mixture
with polysorbate 80 (Figure 5e), a missing signal in the large peak that goes from 2800 to 3000 cm−1
was noticed. Its wavenumber (2950 cm−1) was characteristic of the CH3 groups of FEN. Furthermore,
the signal at 1600 cm−1 from the carbonyl stretching region, present in the FEN (Figure 5a) and both
physical mixtures (Figure 5d,e), was missing from the drug-loaded microfibers’ spectrum. This might
indicate that FEN was present in an amorphous form in the drug-loaded electrospun microfibrous
samples [43–45].
PALS measurements were carried out with the aim of monitoring the supramolecular alterations
through o-Ps lifetime changes of physical mixtures, and the electrospun neat and FEN-loaded
fibrous samples.
Along with the increase of the o-Ps lifetime values, the free volume holes within the polymeric
chains also increased. Figure 6 illustrates that the samples with polysorbate 80 had remarkably
higher o-Ps lifetime values than those of the other samples, either powder mixtures or fibers that
lack polysorbate. This was due to the fact that the presence of polysorbate plasticized the fiber-base
polymer both in the physical mixtures and in the fibrous samples, which could also have relevance for
applications requiring the rigidity of the fibers to be decreased.
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FEN-loaded, PVP-based microfibrous mats were prepared from polysorbate-80-containing 
viscous alcoholic solutions. The SEM studies of the prepared mats revealed homogenous, smooth 
filaments with a microfibrous structure. Complementary analytical methods provided 
intramolecular-level characterization (FTIR and PALS) of the electrospun fibrous samples. The mats 
presented rapid disintegration with immediate drug release, presenting an over 40-fold dissolution 
rate enhancement in water when compared to the micronized active ingredient. The obtained results 
could pave the way for further FEN formulations with enhanced biopharmaceutical characteristics. 
Figure 6. Average o-Ps lifetime values of various samples. neat NF: PVP-based microfibers without
polysorbate 80 and FEN; drug-loaded NF: PVP-based microfibers with polysorbate 80 and FEN;
drug-loaded PM_1: physical mixture containing PVP and FEN; drug-loaded PM_2: physical mixture
containing PVP, fenofibrate, and polysorbate 80.
4. Conclusions
FEN-loaded, PVP-based microfibrous mats were prepared from polysorbate-80-containing viscous
alcoholic solutions. The SEM studies of the prepared mats revealed homogenous, smooth filaments
with a microfibrous structure. Complementary analytical methods provided intramolecular-level
characterization (FTIR and PALS) of the electrospun fibrous samples. The mats presented rapid
disintegration with immediate drug release, presenting an over 40-fold dissolution rate enhancement
in water when compared to the micronized active ingredient. The obtained results could pave the way
for further FEN formulations with enhanced biopharmaceutical characteristics.
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